Archer 1009 results

2020-02-18 12:02

Study Results ARCHER 1009. . 110 Study A (Study 1011): A DoubleBlind Placebo Controlled Randomized Trial of PF804 In Patients With Incurable StageMay 25, 2011 ARCHER 1009: A Study Of Dacomitinib (PF ) Vs. Erlotinib In The Treatment Of Advanced NonSmall Cell Lung Cancer (ARCHER 1009) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. archer 1009 results

May 25, 2011 ARCHER 1009: A Study Of Dacomitinib (PF ) Vs. Erlotinib In The Treatment Of Advanced NonSmall Cell Lung Cancer (ARCHER 1009) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U. S. Federal Government.

Based on these encouraging Phase II results for dacomitinib compared with erlotinib, including benefit across multiple molecular and clinical subsets, a PhaseIII trial, the ARCHER (1009) study, has been initiated. ARCHER (1009) study This is a multinational, multicenter, randomized, doubleblinded, doubledummy, Phase III clinical trial Oct 15, 2015 The results of ARCHER 1009 indicated there is no difference in terms of efficacy between dacomitinib and erlotinib as secondline treatment of unselected NSCLC regardless of histology, but more toxicities with dacomitinib.archer 1009 results ARCHER 1009 Study (Advanced Research for Cancer targeted panHER therapy): Dacomitinib (PF ), a panHER inhibitor, vs Erlotinib in second or thirdline therapy for advanced non small cell lung cancer (NSCLC) Dacomitinib (PF ) is an investigational agent and has not been approved for marketing by any regulatory

Rating: 4.81 / Views: 649

Archer 1009 results free

Jan 27, 2014 An ongoing, third Phase 3 trial, ARCHER 1050, is evaluating PFS of dacomitinib in a different patient population than was studied in ARCHER 1009 and BR26. ARCHER 1050 compares dacomitinib versus gefitinib in treatmentnave (without prior treatment) patients with EGFRmutant advanced NSCLC. The results are expected in 2015. archer 1009 results ARCHER 1009 Trial. The ARCHER 1009 trial did not prove successful. It did not meet the primary objective of statistical improvement in progressionfree survival (PFS). Compared to erlotinib, an EGFR inhibitor, dacomitinib was not superior. The study included two populations of people with NSCLC who had previously received chemotherapy treatment. Dacomitinib versus erlotinib in patients with advancedstage, previously treated nonsmallcell lung cancer (ARCHER 1009): a randomised, doubleblind, phase 3 trial. results of ARCHER 1050 and LUX Lung 7 could provide definitive proof and guidance for optimum firstline treatment of patients with EGFR mutant nonsmallcell lung cancer. 1009 Archer St, Houston, TX is a single family home that contains 952 sq ft and was built in 1924. It contains 2 bedrooms and 1. 5 bathrooms. The Zestimate for this house is 296, 369, which has increased by 5, 343 in the last 30 days. An ongoing, third Phase 3 trial, ARCHER 1050, is evaluating PFS of dacomitinib in a different patient population than was studied in ARCHER 1009 and BR26. ARCHER 1050 compares dacomitinib versus gefitinib in treatmentnave (without prior treatment) patients with EGFRmutant advanced NSCLC. The results are expected in 2015.